Longeveron Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LGVN research report →
Companywww.longeveron.com
Longeveron Inc. , a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors.
- CEO
- Stephen H. Willard
- IPO
- 2021
- Employees
- 25
- HQ
- Miami, FL, US
Price Chart
Valuation
- Market Cap
- $15.39M
- P/E
- -0.78
- P/S
- 12.66
- P/B
- 1.09
- EV/EBITDA
- -0.02
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 65.13%
- Op Margin
- -1881.66%
- Net Margin
- -1844.49%
- ROE
- -202.41%
- ROIC
- -130.35%
Growth & Income
- Revenue
- $1.20M · -49.87%
- Net Income
- $-22,704,000 · -42.14%
- EPS
- $-1.29 · -20.56%
- Op Income
- $-23,287,000
- FCF YoY
- -27.12%
Performance & Tape
- 52W High
- $1.80
- 52W Low
- $0.47
- 50D MA
- $0.94
- 200D MA
- $0.76
- Beta
- -0.32
- Avg Volume
- 5.75M
Get TickerSpark's AI analysis on LGVN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 1, 26 | Lehr Paul T | other | 250,000 |
| May 1, 26 | Willard Stephen H | other | 500,000 |
| May 1, 26 | Blass Devin | other | 250,000 |
| May 1, 26 | Agafonova Nataliya | other | 250,000 |
| May 1, 26 | Locklear Lisa | other | 250,000 |
| Apr 1, 26 | Lehr Paul T | other | 5,611 |
| Apr 1, 26 | Agafonova Nataliya | other | 13,145 |
| Apr 1, 26 | Locklear Lisa | other | 13,145 |
| Apr 1, 26 | Willard Stephen H | other | 4,740 |
| Apr 1, 26 | Blass Devin | other | 8,633 |
Our LGVN Coverage
We haven't published any research on LGVN yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate LGVN Report →